Research Article

Moxibustion for Herpes Zoster and Postherpetic Neuralgia: A Meta-Analysis

Yuanen Huang, Jingping Wu, Hongbin Cheng, and Yanling Liu

1Clinical Research on Skin Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China
2Department of Medical Cosmetology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China
3Dermatology Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China
4Surgery of Chinese Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China

Correspondence should be addressed to Hongbin Cheng; hongbincheng2007@126.com

Received 19 January 2021; Accepted 4 May 2021; Published 22 May 2021

Academic Editor: Wei Wang

Copyright © 2021 Yuanen Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Herpes zoster (HZ) is a disease that mainly causes severe segmental neuralgia and vesicles after infection with herpes zoster virus (VZV). At the same time, more than 9 to 34 percent of patients have postherpetic neuralgia (PHN) present with chronic pain for months or even years. Moxibustion has been used to treat herpes zoster and postherpetic neuralgia for many years; however, there has been no comprehensive study to evaluate the efficacy and safety of moxibustion in the treatment of herpes zoster and postherpetic neuralgia. More studies evaluated the combined effects of acupuncture and moxibustion. Therefore, the purpose of this systematic review is to evaluate their efficacy and safety, so as to provide an evidence-based basis for the clinical application of moxibustion in the treatment of HZ and PHN.

Method. The literature search was conducted in nine Chinese and English databases, and randomized controlled trials were pooled from their inception to June 2020. The included literature was screened, and data were extracted. RevMan 5.3 software and Stata software were used for statistical analysis. The primary outcome was the total effect. The secondary outcomes include VAS, NRS, and time of analgesia.

Outcomes. From a total of 1957 identified studies, 31 were included in analysis (N = 2334 cases). 31 RCTs contained the experimental sample of 1185 cases and the control sample of 1149 cases reported efficiency of different moxibustions in the treatment of herpes zoster, statistical heterogeneity inspection without heterogeneity. So, we used the fixed-effects model, merge effect quantity OR = 3.89 (95% CI: 2.88–5.25), Z = 8.86, and it suggested sample merger analysis was statistically significant. Also, the moxibustion, compared to other methods in the treatment of herpes zoster and herpes zoster neuralgia efficiency, increased significantly. The VAS scales, WMD = 1.69 (95% CI: 1.17–2.22), and the time of analgesia, WMD = 2.41 (95% CI: 3.26–1.73), indicated that moxibustion surpassed others in the relief of pain. NRS was just reported in one study. It was not statistically significant. There was no significant difference in adverse effects OR = 0.61 (95% CI: 0.33–1.13), Z = 1.56 (P = 0.12). Conclusion. Moxibustion has obvious advantages over other therapies in the treatment of HZ and PHN. However, due to the obvious publication bias, the interpretation of the results should be cautious, and more rigorous randomized controlled clinical studies should be included to further confirm the results in the future.

1. Introduction

Herpes zoster (HZ) is known as snake-like sore, fire girdle sore, or spider sore in traditional Chinese medicine. The cause of disease has not been determined; at present, it is believed that the pathogenesis is that, after the initial infection of varicella zoster virus in people with low immunity (mostly children), the virus is latent in the ganglion of the posterior root of the spinal cord. After being activated by various incentives, the virus grows and multiplies in the neurons, leading to ganglion inflammation and neuralgia. The virus then travels with the nerve to the skin and causes...
segmental vesicles [1]. Neuralgia can present as tingling, itching, burning, etc., which is one of the most typical symptoms of HZ. Studies have shown that postherpetic neuralgia (PHN) occurs in more than 9 to 34 percent of patients, with chronic pain lasting months or years having detrimental effects on sleep, daily activities, and quality of life [2].

Western medicine treats herpes zoster with antiviral, nourishing nerve, anti-inflammatory and analgesic methods, and tricyclic antidepressants, opioids, gabapentin, lidocaine patch, capsaicin, and other therapies in pain relief, but the efficacy is limited [3], and the drug’s side effects on patients also limit its use [4], while acupuncture and moxibustion combined therapy has a better performance in relieving pain and relieving symptoms [5–7]. Meanwhile, the study of Li et al. [8] showed that the use of acupuncture and moxibustion therapy is cheaper than Western medicine in cost so as to reduce the financial burden of patients.

Moxibustion therapy is a method of burning and ironing the acupoints or diseased parts by means of the heat of moxibustion fire and the action of drugs, so as to warm the meridians to dissipate the cold, nourish the Yang to get rid of the stasis, dissipate the knot, induce heat to the outside, and prevent diseases and health care. There are many kinds of moxibustion, moxibustion from medicine, white mustard moxibustion, fine moxibustion, Cantharide moxibustion, and so on); moxibustion methods are divided into direct moxibustion, indirect moxibustion, suspension moxibustion, practical moxibustion, and so on [9]. Different methods have different directions of action, but the thermodermal action is a common feature. Kai-Yu et al. [10] and Petersen [11] found that warm stimulation of moxibustion could improve skin permeability, promote wound healing, drug percutaneous absorption, and treat skin infectious diseases, indirectly proving that moxibustion may have its unique advantages in the treatment of herpes zoster and neuralgia.

Research shows that, in clinical practice, use of different moxibustions combined with acupuncture, internal and external use of drugs, phototherapy, and other methods in the treatment of herpes zoster has a significant effect, but many studies focus more on the effectiveness of acupuncture and moxibustion comprehensive therapy (including acupuncture and moxibustion, cupping, and so on), treatment of herpes zoster, and action mechanism [5, 12, 13]. There is a lack of independent evaluation of moxibustion therapy in the treatment of HZ and PHN in the literature. Thus, the purpose of this study was to evaluate the effectiveness of moxibustion in relieving the neuralgia caused by HZ and PHN in a more comprehensive, systematic, and rigorous way, to make up the blank of moxibustion research in the treatment of HZ and PHN, meanwhile, to provide reliable evidence for the treatment of HZ and PHN by use of moxibustion.

2. Methods

2.1. Literature Search. Five English (PubMed, Embase, Cochrane Central, Web of Science, and Springer Link) and four Chinese (CBM, CNKI, CQVIP, and Wanfang Data) databases were searched from inception to June 2020. Search terms were grouped according to condition (herpes zoster, zoster, neuralgia, postherpetic neuralgia, and variants), intervention (acupuncture, moxibustion, and variants), and study design (randomized, controlled, and variants).

2.2. Eligibility Criteria

2.2.1. Types of Studies. Any randomized trials, whether double-blind, single-blind, or unblinded, and regardless of publication status, language and length of trial were considered for inclusion. When administering moxibustion, patients are typically aware of methods. This makes blinding difficult. In this study, there were no special requirements for blinding subjects or administrators.

2.2.2. Types of Participants. Participants with HZ or PHN who were adults (>18 years), regardless of sex or ethnicity, were included in this study. There are definite diagnostic criteria for HZ. Because PHN’s diagnostic criteria are inconsistent, we defined PHN as pain persisting for more than 1 month or any of the abovementioned criteria included into the literature.

2.2.3. Types of Interventions and Controls. If the experimental intervention is moxibustion, the control intervention can be one or more other therapies including acupuncture, drugs, cupping, and phototherapy, except moxibustion. If the experimental intervention is moxibustion combined with other therapies, the control intervention must be the same as other therapies in the experimental group.

2.2.4. Types of Outcomes. Primary outcome will be the efficiency of patients’ condition improvement. Secondary outcome will include pain intensity (measured by the Visual Analogue Scale (VAS), Numerical Rating Scale (NRS), and the time of analgesia) and adverse effects (including infection and empyrosis).

2.2.5. Treatment Cycle. The two groups had the same treatment cycle, or the outcome was cure.

2.3. Exclusion Criteria

2.3.1. Types of Participants. Participants with complications of herpes zoster (Ramsay Hunt syndrome, zoster ophthalmicus, zoster sine herpete, visceral or disseminated zoster, and bacterial infections) or included immunocompromised patients (e.g., HIV, cancer, diabetes, pregnant, or breastfeeding) will be excluded.

2.3.2. Sample Size. Studies with a sample size of less than 30 in the experimental group and/or control group will be ineligible.
2.3.3. Experimental Data. It is rejected if the experimental description is unclear or the experimental data are incorrect or inaccurate so that it cannot be extracted; meanwhile, the studies' authors cannot be contacted to obtain the data.

2.4. Extraction of Data. Retrieval results were imported into literature management software Endnote X9 for review. According to titles and abstracts, two researchers independently screened studies. If titles and abstracts could not determine whether the studies could be included, the full text is reviewed. At the same time, the two researchers independently extracted data from included literatures into a predefined spreadsheet, including the title, author, year, treatment cycle, sample size, interventions, effective events, lost to exit, follow-up time, adverse reactions, and the Jadad score. If there was a difference, it would be solved by two researchers with a third researcher through discussion.

2.5. Quality Assessment. Quality assessment was made independently by two researchers. The two researchers independently used the modified Jadad Scale and the Cochrane Collaboration's risk of bias tool to cross check the quality of the literature. The modified Jadad scale evaluates the literature from four aspects: “random sequence generation,” “random hiding,” “blind method,” and “loss to follow-up and exit.” A score of 1–3 is of low quality and 4–7 is of high quality. The Cochrane Collaboration’s risk of bias tool assesses from 7 aspects: “random sequence generation,” “random concealment,” “blind subjects and interveners,” “blind evaluators,” “complete reporting of outcome data,” “selective reporting of study results,” and “other biases.” The risk of bias for each item would be graded as “low risk of bias,” “unclear risk of bias,” or “high risk of bias.” If disagreement was seen in assessments, this was resolved through discussion with a third researcher.

2.6. Date of Analysis. RevMan 5.3 software and Stata software were used for data statistics (The Nordic Cochrane Centre). Continuous data were presented as weighted mean difference (WMD) or standardized mean difference (SMD), and dichotomous data were presented as odds ratio (OR), with 95% confidence intervals (CI). A Z test was used for the statistical hypothesis test, and the test level was set as $P = 0.05$. $I^2$ was used for quantitative analysis of statistical heterogeneity. When $P > 0.05$ and $I^2 < 50\%$, all studies were statistical homogeneous, and a fixed-effects model (FE) was used for analysis. When $P < 0.10$, $I^2 > 50\%$, statistical heterogeneity was considered present, and a random-effects model (RE) was used for analysis. If 10 or more studies were included in a meta-analysis, we would explore publication bias through the funnel regression method or Egger’s regression method. Sensitivity analysis was carried out using the trim and fill method and one-by-one removal method.

3. Results

3.1. Description of Studies. 1669 Chinese citations and 288 English citations were searched from the database, and 891 duplicate references were excluded. 884 citations were excluded based on screening of titles and abstracts, and 182 citations were reviewed in full text. 31 randomized controlled trials (RCTs) met the inclusion criteria. The studies' screening is shown in Figure 1. There are 19 RCTs about HZ and 12 RCTs about PHN, the total number of participants was 2334, and the characteristics of participants in included studies are shown in Figure 2. All studies were conducted in China. Six studies included more than one treatment group, and those additional treatment arms were excluded from this review [14–19].

3.2. Risk of Bias in Included Studies. The total score of improved Jadad is 7 points, with 27 articles of low quality scoring 1–3 points and 4 articles of high quality scoring 4–7 points.

The recommendations in the methods section of the Cochrane Handbook 5.3.3 were used to assess the risk of bias. All included studies mentioned the randomization methods used. 19 studies used a random number table to divide patients into experimental and observation groups. Two studies used a computer-generated random number, one study used central random distribution, eight studies just mentioned only random words, and one study was randomly assigned in the order of visits. Four studies used distribution of hidden. Three studies mentioned blinding details for evaluators and statisticians. Seven studies described the number and reason of shedding, one study only described the number of shedding, and one study did not describe the number of shedding.

A study had a mistake in date [20], a study’s was not described in detail [21], and others found no significant source bias after reviewing the full text (Figures 3 and 4).

3.3. Curative Effect Analysis

3.3.1. Primary Outcome Efficiency. 31 RCTs [14–44] containing the experimental sample of 1185 cases and the control sample of 1149 cases reported efficiency of different moxibustions in the treatment of herpes zoster, statistical heterogeneity inspection without heterogeneity ($P = 0.98$, $I^2 = 0\%$). So, we used the fixed-effects model, merge-effect quantity $OR = 3.89$ (95% CI: 2.88–5.25), $Z = 8.86$ ($P < 0.00001$); it suggested sample merger analysis was statistically significant. Also, the moxibustion’s efficiency, compared to other methods in the treatment of herpes zoster and herpes zoster neuralgia, increased significantly (Figure 5).

3.3.2. Secondary Outcome VAS and NRS. The 20 studies [14, 16–19, 22, 24–29, 31, 32, 35–38, 42, 43] involved 733 patients in the experimental group and 718 patients in the control group. VAS before and after treatment were reported, and the difference in VAS before and after treatment was calculated. The heterogeneity test showed high heterogeneity ($P < 0.00001$, $I^2 = 88\%$), WMD = 1.69 (95% CI: 1.17–2.22), $Z = 6.32$ ($P < 0.00001$), indicating that the
combined analysis of the samples in the studies were statistically significant. Compared with other nonmoxibustion methods, the difference in VAS before and after treatment with moxibustion for herpes zoster and herpes zoster neuralgia was larger than that of other therapies, indicating that moxibustion could better relieve pain than other therapies (Figure 6).

NRS was reported in one study [40]. WMD $= 0.71$ (95% CI: $-0.87 \sim 2.29$), indicating that the combined analysis of the samples in the study was not statistically significant. It did not show that moxibustion relieves the pain better than other therapies. Heterogeneity was not applicable because the number of studies included was insufficient (Figure 7).

3.3.3. The Time of Analgesia. 16 studies [14–17, 20, 21, 23, 25, 30, 33, 34, 36, 38, 39, 41, 44] involving sample group 645 cases and control group 622 cases reported the patient’s pain time, and heterogeneity inspection shows high heterogeneity ($P < 0.00001$, $I^2 = 91\%$); by using the random-effects model, merge effect quantity of WMD $= 2.41$ (95% CI: 3.26–1.73), $Z = 6.32$ ($P < 0.00001$), suggesting the studies’ samples merger analysis was statistically significant, compared with other methods of moxibustion and moxibustion could shorten the time of herpes zoster and herpes zoster neuralgia pain significantly (Figure 8).

3.4. Adverse Effects. 12 studies [15–17, 19, 26, 27, 29, 31, 33, 35, 36, 38] just mentioned “adverse effects,” including 7 studies reporting adverse reactions, involved in experimental group 451 cases and control group 447 cases. Heterogeneity analysis ($P = 0.19$, $I^2 = 31\%$), using the fixed-effects model, merge effect quantity OR $= 0.61$ (95% CI: 0.33–1.13), $Z = 1.56$ ($P = 0.12$), and merge effect quantity had no statistical significance in the studies, which cannot explain that there was no difference between moxibustion and nonmoxibustion in treating herpes zoster and neuralgia (Figure 9). No serious adverse reactions were found in the 31 RCTs.

3.5. Publication Bias. The funnel plot was drawn to show the asymmetry of scatter point distribution, and Egger’s regression method was used to test publication bias. Egger’s test showed $t = 9.39$ ($P < 0.001$, 95% CI: 1.78–2.77);
### Table: Characteristics of participants in included studies.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Sample size (E/C)</th>
<th>Design of study</th>
<th>Baseline comparability</th>
<th>Intervention</th>
<th>Control group</th>
<th>Outcome measures</th>
<th>Generation of random sequences</th>
<th>Inclusion</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChengYu Lei</td>
<td>2019</td>
<td>30/30</td>
<td>RCT</td>
<td>Y</td>
<td>Thunder and fire moxibustion + famciclovir</td>
<td>Famciclovir</td>
<td>○○</td>
<td>Random number table method</td>
<td>0</td>
<td>13</td>
</tr>
<tr>
<td>Dan Wang</td>
<td>2015</td>
<td>35/30</td>
<td>RCT</td>
<td>Y</td>
<td>Moxibustion + heat-sensitive acupuncture + longinum needle + aciclovir + etc</td>
<td>Longinum needle + aciclovir + etc</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>30</td>
</tr>
<tr>
<td>DongBo Cao</td>
<td>2018</td>
<td>43/43</td>
<td>RCT</td>
<td>Y</td>
<td>Western medicine + traditional Chinese medicine + thermal moxibustion</td>
<td>General drug + traditional Chinese medicine</td>
<td>○○</td>
<td>Random number table method</td>
<td>1</td>
<td>N</td>
</tr>
<tr>
<td>EnYu Zhang</td>
<td>2004</td>
<td>30/30</td>
<td>RCT</td>
<td>Y</td>
<td>Circulating moxibustion</td>
<td>Laser</td>
<td>○○</td>
<td>Random number table method</td>
<td>1</td>
<td>N</td>
</tr>
<tr>
<td>EnYu Zhang</td>
<td>2019</td>
<td>32/32</td>
<td>RCT</td>
<td>Y</td>
<td>Needle warming through moxibustion</td>
<td>Acupuncture</td>
<td>○○</td>
<td>Random number table method</td>
<td>1</td>
<td>N</td>
</tr>
<tr>
<td>FeiLi Hu</td>
<td>2013</td>
<td>63/63</td>
<td>RCT</td>
<td>Y</td>
<td>Circulating moxibustion + general drug</td>
<td>Compound calcium loten + general drug</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>60</td>
</tr>
<tr>
<td>Feng Chen</td>
<td>2014</td>
<td>30/30</td>
<td>RCT</td>
<td>Y</td>
<td>Intramuscular moxibustion + electro-acupuncture + predicing cupping moxibustion method</td>
<td>Electro-acupuncture + predicing cupping moxibustion method</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>30</td>
</tr>
<tr>
<td>GuoFu Huang</td>
<td>2012</td>
<td>35/36</td>
<td>RCT</td>
<td>Y</td>
<td>Cotton moxibustion</td>
<td>Valaclovir + vitamin b1</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>60</td>
</tr>
<tr>
<td>GuoMing Pu</td>
<td>2017</td>
<td>60/60</td>
<td>RCT</td>
<td>Y</td>
<td>Cotton moxibustion</td>
<td>Valaclovir</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>90</td>
</tr>
<tr>
<td>HongQing Ma</td>
<td>2008</td>
<td>33/33</td>
<td>RCT</td>
<td>Y</td>
<td>Acupuncture at jiaji point</td>
<td>Acupuncture at jiaji point</td>
<td>○○</td>
<td>Random number table method</td>
<td>5</td>
<td>60</td>
</tr>
<tr>
<td>Hui Zhou</td>
<td>2020</td>
<td>32/32</td>
<td>RCT</td>
<td>Y</td>
<td>Grain-mobilization-surround moxibustion + general drug</td>
<td>General drug</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>HuiFen Pan</td>
<td>2009</td>
<td>35/35</td>
<td>RCT</td>
<td>Y</td>
<td>Cotton moxibustion</td>
<td>Western medicine</td>
<td>○○</td>
<td>Random number table method</td>
<td>1</td>
<td>N</td>
</tr>
<tr>
<td>Ju Liu</td>
<td>2009</td>
<td>55/54</td>
<td>RCT</td>
<td>Y</td>
<td>Cotton moxibustion + acupuncture + accuactor</td>
<td>Tapping and moxibustion</td>
<td>○○○○</td>
<td>Central random</td>
<td>6</td>
<td>90</td>
</tr>
<tr>
<td>Jing Yu</td>
<td>2011</td>
<td>30/30</td>
<td>RCT</td>
<td>Y</td>
<td>Tubing moxibustion + surrounded needling</td>
<td>Surrounded needling</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>JunWei Kan</td>
<td>2013</td>
<td>33/33</td>
<td>RCT</td>
<td>Y</td>
<td>Grain-mobilization + acupuncture at jiaji point</td>
<td>Acupuncture at jiaji point</td>
<td>○○</td>
<td>Random number table method</td>
<td>6</td>
<td>60</td>
</tr>
<tr>
<td>Ling Qu</td>
<td>2015</td>
<td>40/40</td>
<td>RCT</td>
<td>Y</td>
<td>Grain-mobilization + routine acupuncture + paravertical points electroacupuncture + etc</td>
<td>Electro-acupuncture + paravertical points electroacupuncture + etc</td>
<td>○○</td>
<td>Random table method</td>
<td>3</td>
<td>90</td>
</tr>
<tr>
<td>Min Zhang</td>
<td>2007</td>
<td>36/36</td>
<td>RCT</td>
<td>Y</td>
<td>Surrounding moxibustion + acupuncture + accuactor</td>
<td>Electro-acupuncture</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>Qing Wang</td>
<td>2017</td>
<td>59/59</td>
<td>RCT</td>
<td>Y</td>
<td>Surrounding moxibustion + acupuncture + accuactor</td>
<td>Electro-acupuncture</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>RenGuan Cao</td>
<td>2018</td>
<td>30/30</td>
<td>RCT</td>
<td>Y</td>
<td>Cotton mobilization + aciclovir + etc</td>
<td>Aciclovir</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>90</td>
</tr>
<tr>
<td>RenXing Yang</td>
<td>2018</td>
<td>30/30</td>
<td>RCT</td>
<td>Y</td>
<td>Warm mobilization + valaclovir + vitamin b1</td>
<td>Valaclovir + vitamin b1</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>XiaoQing Qian</td>
<td>2017</td>
<td>31/31</td>
<td>RCT</td>
<td>Y</td>
<td>Suspension mobilization + general drug</td>
<td>General drug</td>
<td>○○</td>
<td>The software generates randomnumber</td>
<td>6</td>
<td>30</td>
</tr>
<tr>
<td>XiaoYang Zhang</td>
<td>2018</td>
<td>30/30</td>
<td>RCT</td>
<td>Y</td>
<td>Cotton mobilization + filiform needle puncture</td>
<td>Filiform needle puncture</td>
<td>○○○○</td>
<td>Random number table method</td>
<td>2</td>
<td>28</td>
</tr>
<tr>
<td>Xin Zhang</td>
<td>2016</td>
<td>30/30</td>
<td>RCT</td>
<td>Y</td>
<td>Thunder and fire mobilization + surrounding mobilization</td>
<td>Surrounding needling</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>Yan De</td>
<td>2014</td>
<td>40/40</td>
<td>RCT</td>
<td>Y</td>
<td>Herbalismot mobilization</td>
<td>Indomethacin enteric-coated tablets</td>
<td>○○</td>
<td>The software generates randomnumber</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>Yan Li</td>
<td>2006</td>
<td>40/38</td>
<td>RCT</td>
<td>Y</td>
<td>Moxa stick mobilization + acupuncture + accuactor</td>
<td>Acupuncture + etc</td>
<td>○○</td>
<td>Random number table method</td>
<td>1</td>
<td>60</td>
</tr>
<tr>
<td>Yan Tong</td>
<td>2014</td>
<td>54/54</td>
<td>RCT</td>
<td>Y</td>
<td>Mobilization + needlewarmingthrough mobilization + acupuncture at jiaji point</td>
<td>Acupuncture at jiaji point</td>
<td>○○</td>
<td>Random number table method</td>
<td>3</td>
<td>90</td>
</tr>
<tr>
<td>YangHao Qu</td>
<td>2019</td>
<td>40/40</td>
<td>RCT</td>
<td>Y</td>
<td>Warm mobilization + aciclovir</td>
<td>Aciclovir</td>
<td>○○○○</td>
<td>Random number table method</td>
<td>2</td>
<td>60</td>
</tr>
<tr>
<td>YongDui Ruan</td>
<td>2009</td>
<td>31/31</td>
<td>RCT</td>
<td>Y</td>
<td>Thermal mobilization</td>
<td>Acupuncture + cupping</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>YuLin Zhang</td>
<td>2017</td>
<td>45/45</td>
<td>RCT</td>
<td>Y</td>
<td>Warm mobilization</td>
<td>Aciclovir + vitamin b2</td>
<td>○○</td>
<td>Random number table method</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>ZhaiFang Tang</td>
<td>2013</td>
<td>42/38</td>
<td>RCT</td>
<td>Y</td>
<td>Warm mobilization</td>
<td>Western medicine</td>
<td>○○</td>
<td>Random number table method</td>
<td>1</td>
<td>N</td>
</tr>
<tr>
<td>ZhongWei Wen</td>
<td>2019</td>
<td>30/30</td>
<td>RCT</td>
<td>Y</td>
<td>Herbalismot mobilization combined with famciclovir</td>
<td>Famciclovir</td>
<td>○○</td>
<td>Random number table method</td>
<td>1</td>
<td>N</td>
</tr>
</tbody>
</table>

**Figure 2: Characteristics of participants in included studies.**

- Random sequence generation (selection bias)
- Allocation concealment (selection bias)
- Blinding of participants and personnel (performance bias)
- Blinding of outcome assessment (detection bias)
- Incomplete outcome data (attrition bias)
- Selective reporting (reporting bias)

**Figure 3: Risk of bias scale graph.**

- Low risk of bias
- Unclear risk of bias
- High risk of bias

*VAs* • *NRS* • The time of analgesia • Effective ratio • Sequelae • AD: adverse reaction; E: Experimental group; C: Control group.
meanwhile, the regression line in the graph did not go through the origin, it hinted the existence of publication bias, and publication bias led to asymmetry of the funnel plot (Figures 10–12).

3.6. Sensitivity Analysis. Due to publication bias in the included studies, the sensitivity analysis was carried out on the method of the changes of the observation results after being eliminated one by one in the 31 included studies and trim and fill method by STATA software after the supplementary funnel plot ($P < 0.001$) was little changed compared with that before the supplementary funnel plot. The results showed little change after the study was eliminated one by one, indicating that the results were stable (Figures 13–15).

4. Discussion

HZ and PHN brought about a huge pain and economic burden on people around the world [45]. They seriously
Table 1: Results of the meta-analysis involving 31 RCTs. Moxibustion has obvious advantages in the treatment of HZ and PHN, compared with other nonmoxibustion methods, and the analgesic time and VAS concerned in this study performed better in the experimental group than the control group. In this study, inclusion and exclusion criteria were strictly implemented. Clear diagnostic criteria, efficacy evaluation criteria, simple intervention measures, and appropriate sample size enabled the study to have a high level of evidence, which could provide more reliable evidence-based medical evidence for clinical practice.

Limitations: (1) All the included citations in this study were in Chinese, and there was no RCT study in English. (2) Without manual retrieval, grey reference may be omitted. (3) The quality of the included reference is generally low, some studies have no detailed description of random affection people’s health and interfere with the normal life work [46]. Two studies [47, 48] had shown that age, sex, and low immunity were significantly associated with onset, recurrence, and complication. The aging of the population is increasing the burden of the disease on the society. The global incidence of the disease is increasing year by year, about 3–5/1000 person-year, with a recurrence rate of 12/1000 person-year [47, 49]. Antiviral drugs effective against HZ showed no improvement in the relief of PHN, and so far, there is no satisfactory treatment for PHN [50, 51], so researchers and doctors can only recommend shingles vaccine for the elderly to reduce HZ and PHN [52, 53], while there has been no clear report on the effectiveness of vaccination in patients with severe immunodeficiency disease [54, 55]. Therefore, to explore the effective treatment of HZ and PHN is still the direction of the efforts of scholars.

From the meta-analysis involving 31 RCTs, moxibustion has obvious advantages in the treatment of HZ and PHN, compared with other nonmoxibustion methods, and the analgesic time and VAS concerned in this study performed better in the experimental group than the control group. In this study, inclusion and exclusion criteria were strictly implemented. Clear diagnostic criteria, efficacy evaluation criteria, simple intervention measures, and appropriate sample size enabled the study to have a high level of evidence, which could provide more reliable evidence-based medical evidence for clinical practice.

Limitations: (1) All the included citations in this study were in Chinese, and there was no RCT study in English. (2) Without manual retrieval, grey reference may be omitted. (3) The quality of the included reference is generally low, some studies have no detailed description of random
### Figure 6: VAS pain score forest plot.

- **Study or subgroup**
  - EnYu Zhang, 2019
  - Dan Wang, 2015
  - HongQing Ma, 2008
  - Hui Zhou, 2020
  - Jia Liu, 2009
  - Jing Yu, 2011
  - Ling Qiu, 2015
  - JunWei Kan, 2013
  - RongJuan Cao, 2018
  - ZhiJuan Wen, 2019
  - ZhiJia Liu, 2011

- **Experimental**
  - Mean: 4.43
  - SD: 3.72
  - Total: 32

- **Control**
  - Mean: 4.46
  - SD: 3.72
  - Total: 32

- **Weight (%)**
  - Total: 100.00

- **Mean difference**
  - IV, random, 95% CI: 0.71 [-0.87, 2.29]

- **Heterogeneity**
  - tau²: 0.98
  - chi²: 156.43
  - I²: 88%

- **Test for overall effect**
  - Z = 3.72 (P = 0.0001)

### Figure 7: NRS funnel plot.

- **Study or subgroup**
  - EnYu Zhang, 2019
  - Dan Wang, 2015
  - HongQing Ma, 2008
  - Hui Zhou, 2020
  - Jia Liu, 2009
  - Jing Yu, 2011
  - JunWei Kan, 2013
  - RongJuan Cao, 2018
  - ZhiJuan Wen, 2019
  - ZhiJia Liu, 2011

- **Experimental**
  - Mean: 4.43
  - SD: 3.72
  - Total: 32

- **Control**
  - Mean: 4.46
  - SD: 3.72
  - Total: 32

- **Weight (%)**
  - Total: 100.00

- **Mean difference**
  - IV, random, 95% CI: 0.71 [-0.87, 2.29]

- **Heterogeneity**
  - tau²: 0.98
  - chi²: 156.43
  - I²: 88%

- **Test for overall effect**
  - Z = 3.72 (P = 0.0001)

### Figure 8: The time of analgesia forest plot.

- **Study or subgroup**
  - EnYu Zhang, 2019
  - Dan Wang, 2015
  - HongQing Ma, 2008
  - Hui Zhou, 2020
  - Jia Liu, 2009
  - Jing Yu, 2011
  - JunWei Kan, 2013
  - RongJuan Cao, 2018
  - ZhiJuan Wen, 2019
  - ZhiJia Liu, 2011

- **Experimental**
  - Mean: 4.43
  - SD: 3.72
  - Total: 32

- **Control**
  - Mean: 4.46
  - SD: 3.72
  - Total: 32

- **Weight (%)**
  - Total: 100.00

- **Mean difference**
  - IV, random, 95% CI: 0.71 [-0.87, 2.29]

- **Heterogeneity**
  - tau²: 0.98
  - chi²: 156.43
  - I²: 88%

- **Test for overall effect**
  - Z = 3.72 (P = 0.0001)
<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Experimental Events</th>
<th>Total</th>
<th>Control Events</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Odds ratio M-H, fixed, 95% CI</th>
<th>Odds ratio M-H, fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>GuoFu Huang, 2012</td>
<td>0</td>
<td>34</td>
<td>0</td>
<td>34</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HongQing Ma, 2008</td>
<td>0</td>
<td>32</td>
<td>0</td>
<td>31</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jia Liu, 2009</td>
<td>5</td>
<td>55</td>
<td>0</td>
<td>54</td>
<td>1.8</td>
<td>11.87 [0.64, 220.17]</td>
<td></td>
</tr>
<tr>
<td>JunWei Kan, 2013</td>
<td>1</td>
<td>32</td>
<td>0</td>
<td>32</td>
<td>1.9</td>
<td>3.10 [0.12, 78.87]</td>
<td></td>
</tr>
<tr>
<td>Ling Qiu, 2015</td>
<td>1</td>
<td>38</td>
<td>1</td>
<td>38</td>
<td>3.7</td>
<td>1.03 [0.06, 17.03]</td>
<td></td>
</tr>
<tr>
<td>Rongjuan Cao, 2018</td>
<td>0</td>
<td>30</td>
<td>4</td>
<td>34</td>
<td>17.2</td>
<td>0.10 [0.01, 1.90]</td>
<td></td>
</tr>
<tr>
<td>XiaoHong Quan, 2017</td>
<td>0</td>
<td>31</td>
<td>0</td>
<td>30</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xin Zhang, 2016</td>
<td>0</td>
<td>30</td>
<td>0</td>
<td>30</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yan Du, 2014</td>
<td>12</td>
<td>40</td>
<td>20</td>
<td>40</td>
<td>54.4</td>
<td>0.43 [0.17, 1.07]</td>
<td></td>
</tr>
<tr>
<td>Yan Teng, 2014</td>
<td>1</td>
<td>34</td>
<td>1</td>
<td>34</td>
<td>3.8</td>
<td>1.00 [0.06, 16.67]</td>
<td></td>
</tr>
<tr>
<td>YingHao Qu, 2019</td>
<td>0</td>
<td>40</td>
<td>4</td>
<td>40</td>
<td>17.3</td>
<td>0.10 [0.01, 1.92]</td>
<td></td>
</tr>
<tr>
<td>YongDui Ruan, 2009</td>
<td>0</td>
<td>51</td>
<td>0</td>
<td>49</td>
<td>Not estimable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>451</td>
<td>447</td>
<td>100.0</td>
<td>0.61</td>
<td>[0.33, 1.13]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>20</td>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: chi² = 8.65, df = 6 (P = 0.19); I² = 31%
Test for overall effect: Z = 8.86 (P < 0.00001)

Figure 9: Adverse reaction forest plot.

Figure 10: Funnel plot.

Begg’s test

adj.kendall’s score (P-Q) = 280
Std. dev. of score = 53.31
Number of studies = 29
z = 5.25
Pr > |z| = 0.000
z = 5.23 (continuity corrected)
Pr > |z| = 0.000 (continuity corrected)

Egger’s test

\[
\begin{array}{cccccc}
\text{Std. eff} & \text{Coef.} & \text{Std. err.} & t & P > |t| & [95% conf. interval] \\
\hline
\text{slope} & -0.0502394 & 0.166517 & -3.02 & 0.006 & -0.0844058 & -0.0160729 \\
\text{bias} & 2.272308 & 0.2419102 & 9.39 & 0.000 & 1.775949 & 2.768667 \\
\end{array}
\]

Figure 11: Begg’s test and Egger’s test.
Figure 12: Egger’s graph.

Figure 13: Sensitivity analysis.
methods, most studies have not mentioned allocation concealment and blindness methods, and diagnostic criteria and efficacy evaluation criteria are not completely unified, all of which can lead to publication bias. (4) Half of the studies did not have follow-up and adverse reactions reported, and there was insufficient evidence for safety evaluation.

5. Conclusions

The moxibustion has certain advantages in treating HZ and PHN and relieving neuralgia. The obvious publication bias affects the credibility of this result, and more high-quality, large-sample randomized controlled clinical studies should be included in the future to improve the credibility of the result. Meanwhile, more rigorous randomized controlled studies and longer follow-up time are expected in the future to provide reliable clinical evidence for the short-term and long-term efficacy and safety evaluation of moxibustion in the treatment of HZ and PHN.

Data Availability

No datasets were generated or analysed during the current study.
Consent
Informed consent was obtained from all individual participants included in the study references.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Acknowledgments
This work was funded by the “Hundred Talents Project” of the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, No. P2020042, and “Hundred Talents Project” of the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.

References


[38] H. Q. Ma, *Clinical Study on the Treatment of Postherpetic Neuralgia by Ashi Point Direct Moxibustion Plus Encircled Needling*, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 2008.


